EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics

Haiyan Zhou iD, Virginia Arechavala-Gomeza iD, Alejandro Garanto iD

Nucleic Acid Therapeutics · 2023

DOI: 10.1089/nat.2023.0001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2023. Verfasst von Haiyan Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, Uni…. Hauptthemen laut MEDLINE: Nucleic Acids. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preclinical evaluation of nucleic acid therapeutics (NATs) in relevant experimental model systems is essential for NAT drug development. As part of COST Action “DARTER” (Delivery of Antisense RNA ThERapeutics), a network of researchers in the field of RNA therapeutics, we have conducted a survey on the experimental model systems routinely used by our members in preclinical NAT development. The questionnaire focused on both cellular and animal models. Our survey results suggest that skin fibroblast cultures derived from patients is the most commonly used cellular model, while induced pluripotent stem cell-derived models are also highly reported, highlighting the increasing potential of this technology. Splice-switching antisense oligonucleotide is the most frequently investigated RNA molecule, followed by small interfering RNA. Animal models are less prevalent but also widely used among groups in the network, with transgenic mouse models ranking the top. Concerning the research fields represented in our survey, the mostly studied disease area is neuromuscular disorders, followed by neurometabolic diseases and cancers. Brain, skeletal muscle, heart, and liver are the top four tissues of interest reported. We expect that this snapshot of the current preclinical models will facilitate decision making and the share of resources between academics and industry worldwide to facilitate the development of NATs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nucleic AcidsAnimalsMiceRNA, Small InterferingOligonucleotides, AntisenseOligonucleotidesModels, Theoretical

Stichwörter der Autor:innen

animal modelsantisense technologycellular modelsefficacymodel systemsnucleic acid therapeutics

Substanzen

Nucleic AcidsRNA, Small InterferingOligonucleotides, AntisenseOligonucleotides

Autor:innen und Institutionen

  • Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
  • NIHR Great Ormond Street Hospital Biomedical Research Center, London, United Kingdom.
  • Nucleic Acid Therapeutics for Rare Disorders (NAT-RD), Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
  • Ikerbasque, Basque Foundation for Science, Bilbao, Spain.
  • Department of Pediatrics, Amalia Children's Hospital, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Haiyan Zhou, Virginia Arechavala-Gomeza, Alejandro Garanto

Förderung

  • Wellcome Trust

Zitieren

APA

Zhou, H., Arechavala-Gomeza, V., & Garanto, A. (2023). Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics. Nucleic Acid Therapeutics. https://doi.org/10.1089/nat.2023.0001

Vancouver

Zhou H, Arechavala-Gomeza V, Garanto A. Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics. Nucleic Acid Therapeutics. 2023. doi:10.1089/nat.2023.0001

BibTeX
@article{Zhou2023,
  author = {Zhou, Haiyan and Arechavala-Gomeza, Virginia and Garanto, Alejandro},
  title = {Experimental Model Systems Used in the Preclinical Development of Nucleic Acid Therapeutics},
  journal = {Nucleic Acid Therapeutics},
  year = {2023},
  doi = {10.1089/nat.2023.0001}
}
Kostenlos starten →